Catalyst Biosciences (NASDAQ:CBIO) Stock Price Up 7.2%

Catalyst Biosciences Inc (NASDAQ:CBIO)’s stock price rose 7.2% during mid-day trading on Thursday . The stock traded as high as $4.66 and last traded at $4.61. Approximately 187,087 shares traded hands during trading, a decline of 32% from the average daily volume of 275,445 shares. The stock had previously closed at $4.30.

Several research firms have weighed in on CBIO. Zacks Investment Research cut Catalyst Biosciences from a “buy” rating to a “hold” rating in a research report on Monday, August 24th. Ci Capital restated a “buy” rating and issued a $18.00 target price on shares of Catalyst Biosciences in a research note on Thursday, August 6th. Finally, Raymond James set a $20.00 target price on Catalyst Biosciences and gave the company an “outperform” rating in a research note on Friday, August 7th.

The stock has a market capitalization of $101.71 million, a P/E ratio of -1.32 and a beta of 2.19. The company has a 50 day simple moving average of $4.89 and a 200-day simple moving average of $5.57.

Catalyst Biosciences (NASDAQ:CBIO) last released its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported ($0.96) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.10). The company had revenue of $1.66 million during the quarter. As a group, equities research analysts anticipate that Catalyst Biosciences Inc will post -3.1 earnings per share for the current year.

Several large investors have recently added to or reduced their stakes in the stock. Engineers Gate Manager LP raised its stake in shares of Catalyst Biosciences by 49.6% during the 2nd quarter. Engineers Gate Manager LP now owns 19,300 shares of the biopharmaceutical company’s stock valued at $113,000 after purchasing an additional 6,400 shares during the period. Public Employees Retirement System of Ohio bought a new position in Catalyst Biosciences in the 2nd quarter worth about $55,000. BlackRock Inc. increased its stake in Catalyst Biosciences by 3.5% in the 1st quarter. BlackRock Inc. now owns 280,751 shares of the biopharmaceutical company’s stock worth $1,227,000 after acquiring an additional 9,563 shares during the last quarter. American International Group Inc. bought a new position in Catalyst Biosciences in the 2nd quarter worth about $63,000. Finally, Geode Capital Management LLC increased its stake in Catalyst Biosciences by 11.3% in the 1st quarter. Geode Capital Management LLC now owns 118,668 shares of the biopharmaceutical company’s stock worth $518,000 after acquiring an additional 12,076 shares during the last quarter. Institutional investors own 63.16% of the company’s stock.

About Catalyst Biosciences (NASDAQ:CBIO)

Catalyst Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on developing medicines to address hematology indications. Its product pipeline includes marzeptacog alfa, a Factor VIIa variant that is in a Phase II/III clinical trial for the prophylactic treatment of individuals with severe hemophilia A and B with inhibitors.

Recommended Story: Fundamental Analysis and Choosing Stocks

Receive News & Ratings for Catalyst Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.